arrow
M

Matthias Augustin

University Medical Center Hamburg-Eppendorf
H指数:78
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Povorcitinib用于非节段型白癜风:两项随机、对照、III期STOP-V试验

2026-11-020
OAAI
From Data to Clinical Decisions in Chronic Wound Care: Evaluation of the Interpretability, Minimal Important Difference, and Smallest Detectable Change of the Wound‐ QoL ‐14 in a Spanish Population

从数据到慢性伤口护理的临床决策:对Wound‐<scp>QoL</scp>‐14在西班牙人群中的可解释性、最小重要差异和最小可检测变化的评估

2026-10-040
OAAI
Wirksamkeit einer Intervention zur Verringerung der Stigmatisierung von Menschen mit Hauterkrankungen unter Fachkräften im Gesundheits- und Körperpflegebereich – eine randomisierte kontrollierte Studie

一项旨在减少卫生与身体护理领域专业人士对皮肤病患者污名化干预措施有效性的随机对照研究

2026-08-210
OAAI
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

德卡鲁昔替尼治疗斑块状银屑病5年安全性和有效性结果:一项随机临床试验的III期开放标签扩展研究

2026-08-070
OA
Patient treatment needs in atopic dermatitis: A real-world cohort study

特应性皮炎患者的治疗需求:一项真实世界队列研究

2026-07-310
OAAI
Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II

贝美克单抗临床应答与患者报告的健康相关生活质量获益之间的关联:BE HEARD I 和 II 研究结果

2026-06-050
OAAI
Keratinocyte Priming by Staphylococcus aureus Reduces HSV-1 Susceptibility

金黄色葡萄球菌对角质形成细胞的预刺激降低了HSV-1的易感性

2026-05-200
OA
Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update

欧洲皮肤病学与性病学学会工作组与外部专家关于 Hidradenitis Suppurativa 生活质量测量的立场声明:更新

2026-05-170
PRE
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations
2026-02-050
OAAI
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

德尔菲共识: 在化脓性汗腺炎中一线使用生物制剂和小分子

2026-01-240
OAAI